ArticleFrontiers in pharmacology2026
Calycosin attenuates LPS-induced microglia inflammatory responses and microglia-mediated synaptic impairment via modulation of TLR4/MyD88/NF-κB signaling pathway.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Neuroinflammation plays an important role in the initiation and progression of central nervous system (CNS) disorders. Calycosin (Caly) has been reported to exert anti-inflammatory and neuroprotective effects. However, little is known about its potential role in microglia-mediated neurotoxicity and the underlying mechanism. The aim of the present study is to investigate whether Caly attenuates LPS-induced inflammatory response in BV2 microglial cells and microglia-mediated neuronal injuries in HT-22 cells. Methods: BV2 cells were stimulated with LPS (1 μg/mL, 24 h) and treated with Caly (5, 10, or 20 μM) or Dex (2 μM). Molecular docking, CETSA, ITDRF Results: Stimulation with LPS could induce BV2 microglial activation, accompanied by the increased expression and secretion of pro-inflammatory mediators, and dysregulation of TLR4/MyD88/NF-κB signaling pathway. CM derived from LPS-stimulated BV2 cells decreased HT-22 cell viability and reduced synaptic plasticity-related protein expression levels. Caly treatment attenuated LPS-induced cytotoxicity and inflammatory responses, and reversed imbalanced expression of TLR4/MyD88/NF-κB signaling pathway in LPS-challenged BV2 cells, as indicated by the reduced Iba-1 fluorescence intensity, decreased mRNA expression levels and secretion of IL-1β, IL-6, and TNF-α, and decreased proteins expression of IL-17, TLR4, MyD88, p-NF-κB/NF-κB and p-IKB/IKB. Caly also increased the expression of the anti-inflammatory phenotype-associated markers CD206 and Arg1, while reducing the pro-inflammatory markers CD86 and iNOS. Moreover, CM derived from Caly-treated BV2 cells partially restored HT-22 cell viability and protein expression of β-Tubulin, PSD95, and Synapsin I. Supplementary experiments in HMC3 and SH-SY5Y cells showed similar anti-inflammatory and synaptic protein-preserving effects. Conclusion: Caly could exert potential effects on suppressing LPS-induced microglia activation and inflammatory responses in immortalized BV2 cells by regulating TLR4/MyD88/NF-κB signaling pathway, and attenuating microglia-mediated neuronal injury and synaptic impairment in immortalized HT-22 cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.